NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 24 Jan 2017 (#3)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.***

Important notices

- Notice of the Publication of the Final Rule on the Federal Policy for the Protections of Human Subjects (Common Rule) (NOT-OD-17-038)

1. Zika Virus (ZIKV) Complications

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PA-17-085) **Type: R21**

Application Due Date: Standard dates & Standard AIDS dates Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research on Zika virus (ZIKV) and its complications. This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects. The last date for submitting an application to PAR-16-106 is January 13, 2017. ZIKV is a single-stranded RNA virus of the Flaviviridae family. It is transmitted to humans primarily through the bites of infected Aedes mosquitos, though both perinatal/in utero and sexual transmission have been reported. Initially discovered in 1947, it has been reported in the Americas since 2014, with a major outbreak in Brazil starting in 2015. Disease is seen in about 20% of infected people and is usually self-limited. However, an association between ZIKV infection in pregnant women and severe microcephaly in their babies has been very concerning. Additionally, the virus has been found in blood, fueling growing concerns about the risk of transfusion-transmission with particular concern over severe outcomes in at risk transfusion recipient populations such as women who are pregnant.

Budget: Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

2. Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-123) **Type: R01**

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA). This FOA will provide support for assays (and associated data analysis) of repository-held samples for studies focused on an NIDDK relevant disease. The review of applications to this FOA will consider both access to repository-held samples and funding for assays using the samples. These studies are expected to generate scientific discoveries on disease mechanisms, disease pathogenic processes, disease progression, or clinical responses. Projects that make good use of the associated data from the clinical trials and studies, the original intent of the clinical study and/or trial are highly encouraged. Exploratory studies and discovery research are encouraged especially when samples are not severely limited, the work is justified, and the goal is consistent with the original intent of the clinical research.

Budget: Application budgets are limited to $250,000 direct costs per year and must reflect the actual needs of the proposed project. The maximum project period is 3 years.

3. Perception and Cognition Research to Inform Cancer Image Interpretation

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-124) **Type: R21**
(PAR-17-125) **R01**

Application Due Date: May 30, 2017; September 26, 2017; May 30, 2018; September 26, 2018; May 30, 2019; September 26, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis. The Exploratory/Developmental Grant (R21) mechanism supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.

Budget: R21 - The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. R01 -Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Juvenile Protective Factors and Their Effects on Aging

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-126) **Type: R01**
(PAR-17-127) **R03**

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to invite: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Studies which involve comparisons between young and old adults will not be supported by this FOA.

Budget: **R01** - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years. **R03** - The combined budget for direct costs for the two-year project period may not exceed $200,000. No more than $100,000 in direct costs may be requested in any single year.

5. Quantitative Imaging Tools and Methods for Cancer Therapy Response

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-128) **Type: UG3/UH3**

Application Due Date: May 9, 2017; September 12, 2017; January 9, 2018; May 9, 2018; September 12, 2018; January 9, 2019; May 9, 2019; September 12, 2019; January 9, 2020Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA). This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. The scientific scope of this FOA includes: Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support; Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials. A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development and optimization of QI tools and methods chosen for study by the investigating team, while the UH3 phase is for the validation of the tools/methods developed in the UG3 phase. The UG3 phase can be no more than 2 years in duration, and the total project cannot exceed 5 years. At completion, UG3 projects will be reviewed by program staff. Those that have met their milestones may be administratively considered by NCI program staff for transition to the UH3 validation phase.

Budget: Application budgets need to reflect the actual needs of the proposed project but must not exceed $300,000 in direct costs for each year of the UG3 phase and $500,000 (direct costs) for each year of the UH3 phase. The proposed project period for the initial development phase (UG3) award may not exceed 2 years. The total UG3/UH3 period of performance may not to exceed 5 years.

6. Quantitative Imaging Tools and Methods for Cancer Response Assessment

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-129) **Type: U01**

Application Due Date: May 9, 2017; September 12, 2017; January 9, 2018; May 9, 2018; September 12, 2018; January 9, 2019; May 9, 2019; September 12, 2019; January 9, 2020Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.

Budget: Application budgets need to reflect the actual needs of the proposed project but must not exceed $500,000 (direct costs) for each proposed year. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - **Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements *(click on "PA" to search for further funding opportunities)*

RFA Request for Applications *(click on "RFA" to search for further funding opportunities)*

Complete Glossary and acronym list of NIH Terms

NIH National Institutes of Health
Turning Discovery Into Health

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa Coetsee*** • Tel: 9838 • Email: cdevries@sun.ac.za